Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Identification of chelerythrine as an inhibitor of BclXL function.

Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, Yu VC.

J Biol Chem. 2003 Jun 6;278(23):20453-6. Epub 2003 Apr 17.

2.

Mechanisms of cytochrome c release by proapoptotic BCL-2 family members.

Scorrano L, Korsmeyer SJ.

Biochem Biophys Res Commun. 2003 May 9;304(3):437-44. Review.

PMID:
12729577
3.

Mitochondrial membrane permeabilisation by Bax/Bak.

Degli Esposti M, Dive C.

Biochem Biophys Res Commun. 2003 May 9;304(3):455-61. Review.

PMID:
12729579
4.

Structural biology of the Bcl-2 family of proteins.

Petros AM, Olejniczak ET, Fesik SW.

Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94. Review.

5.

Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities.

Chan SL, Yu VC.

Clin Exp Pharmacol Physiol. 2004 Mar;31(3):119-28. Review.

PMID:
15008953
6.

Mitochondria and apoptosis: new therapeutic targets.

Hockenbery DM, Giedt CD, O'Neill JW, Manion MK, Banker DE.

Adv Cancer Res. 2002;85:203-42. Review. No abstract available.

PMID:
12374287
7.

BH3-only proteins trigger cytochrome c release, but how?

Häcker G, Weber A.

Arch Biochem Biophys. 2007 Jun 15;462(2):150-5. Epub 2007 Jan 9. Review.

PMID:
17306210
8.
9.

Targeting mitochondria for cancer therapy.

Hockenbery DM.

Environ Mol Mutagen. 2010 Jun;51(5):476-89. doi: 10.1002/em.20552. Review.

PMID:
20213841
10.

Bax, along with lipid conspirators, allows cytochrome c to escape mitochondria.

Hardwick JM, Polster BM.

Mol Cell. 2002 Nov;10(5):963-5. Review. No abstract available.

11.
12.

Protein-protein interfaces: mimics and inhibitors.

Cochran AG.

Curr Opin Chem Biol. 2001 Dec;5(6):654-9. Review.

PMID:
11738175
13.

New dimension in therapeutic targeting of BCL-2 family proteins.

Besbes S, Mirshahi M, Pocard M, Billard C.

Oncotarget. 2015 May 30;6(15):12862-71. Review.

14.

Structure, function and inhibition of Bcl-2 family proteins: a new target for anti-tumor agents.

Xiao G, Fang H, Xing C, Xu W.

Mini Rev Med Chem. 2009 Dec;9(14):1596-604. Review.

PMID:
20236080
15.

Bcl-2 inhibitors: emerging drugs in cancer therapy.

Bodur C, Basaga H.

Curr Med Chem. 2012;19(12):1804-20. Review.

PMID:
22414090
16.

Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

Winfield LL, Payton-Stewart F.

Future Med Chem. 2012 Mar;4(3):361-83. doi: 10.4155/fmc.11.177. Review.

17.

Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications.

Walterová D, Ulrichová J, Válka I, Vicar J, Vavrecková C, Táborská E, Harjrader RJ, Meyer DL, Cerná H, Simánek V.

Acta Univ Palacki Olomuc Fac Med. 1995;139:7-16. Review.

PMID:
8686560
18.

In silico methods for designing antagonists to anti-apoptotic members of Bcl-2 family proteins.

Sivakumar D, Richa T, Rajesh SS, Gorai B, Sivaraman T.

Mini Rev Med Chem. 2012 Oct;12(11):1144-53. Review.

PMID:
22697515
19.

Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

Zeitlin BD, Zeitlin IJ, Nör JE.

J Clin Oncol. 2008 Sep 1;26(25):4180-8. doi: 10.1200/JCO.2007.15.7693. Review.

20.

New strategies for the treatment of ovarian cancer.

Robinson E, Fisher N, Stamelos V, Redman C, Richardson A.

Biochem Soc Trans. 2014 Feb;42(1):125-9. doi: 10.1042/BST20130203. Review.

PMID:
24450639
Items per page

Supplemental Content

Write to the Help Desk